FDA Inspection 1169829 — University Of Texas MD Anderson Cancer Center
The FDA completed an inspection of University Of Texas MD Anderson Cancer Center on May 12, 2022 in Houston, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 12, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Houston, TX (United States)